Acknowledgements We thank our many colleagues who have influenced us in innumerable ways over the years and for being the beneficiary of their collective wisdom. DDW

Dr Anton Fliri is the founder of SystaMedic Inc. He got his PhD in organic chemistry from the University of Innsbruck and advanced his educa- tion as a postdoctoral fellow at Nobel Prize win- ning labs at Harvard and ETH Zurich. He also obtained a JD degree from the University of Hartford specialising in international intellectual property. In his 30-year tenure at Pfizer he accom- plished in the areas of cancer, neuroscience and pattern recognition technology. After leaving Pfizer, he developed analytical tools for analysing system-wide cause-effect relationships that led to the creation of SystaMedic Inc.

Dr Palaniyandi Manivasakam is a co-founder of SystaMedic Inc He holds PhD in molecular Genetics from the University of Alberta, Canada. He completed his post-doctoral training at Harvard in the cancer biology department. His expertise includes Genetics, pharmacogenomics, high throughput screening and big data analytics which were applied to various stages of drug dis- covery and development. He has authored more than 41 publications and has 37 published and eight issued patents. His entrepreneurial experi- ence included co-founding, developing and merg- ing a biotech company, IndUS Pharmaceuticals. Presently, he is leading the new Intellectual Property development and business strategies at SystaMedic Inc. palaniyandi.manivasakam@sys-

Dr Shama Kajiji is a co-founder of SystaMedic Inc. She received her PhD in Pharmacology and Experimental Pathology (Cancer Biology) from Brown University and completed her post-doctoral training in Immunology at Scripps Clinic and Research Foundation, La Jolla, CA where she dis- covered alpha 6 beta 4 integrin. She also earned an Executive MBA from the University of Rhode Island and is a graduate of the Strategic Leadership Programs offered by Harvard and Stanford Universities. Shama spent ~20 years at Pfizer in various positions of responsibilities including Global Head of Attrition Analysis Office. She holds multiple patents and her successful R&D contributions include Tarceva, a marketed drug and Tremelimumab, a monoclonal antibody. In addition to Pfizer, Shama has contributed to the


management and analysis of Global R&D pipelines of Merck Research Labs and Janssen Pharmaceuticals. As CEO of SystaMedic Inc, she is leading the strategic planning and operational objectives of the company. shama.kajiji@sys-

Dr Gerald Lushington is a co-founder, Chief Scientific Officer and Executive Vice-President of TheraPeptics, LLC – a biotech company focused on designing peptide-based therapeutics for neu- rodegenerative disorders, microbial infections and cancer. With more than 180 publications and five US and international patents, his studies entail sim- ulations, visualisation and data analysis techniques for extracting insight from in vitro and in vivo studies in the health and life sciences. He has devel- oped and licensed technology for commercial development to Centaur Animal Health, Inc and supports R&D and commercialisation efforts for a diverse array of clients in academia, government and the pharmaceutical and biotechnology indus- tries. Dr Lushington is an adjunct professor in the Department of Food, Nutrition, Dietetics and Health at Kansas State University. He serves as Editor-in-Chief for the journal Combinatorial Chemistry & High Throughput Screening, Bioinformatics Editor for WebMedCentral and is on editorial boards for Current Bioactive Compounds, Current Enzymology and the Annals of Biotechnology.

Dr Rathnam Chaguturu is the Innovation Czar, Founder & CEO of iDD Partners (Princeton Junction, NJ, USA), a non-profit think-tank focused on pharmaceutical innovation and, most recently, Deputy Site Head, Center for Advanced Drug Research, SRI International. He has more than 35 years of experience in academia and industry, man- aging new lead discovery projects and forging col- laborative partnerships with academia, disease foundations, non-profits and government agencies. He is the Founding President of the International Chemical Biology Society, a Founding Member of the Society for Biomolecular Sciences and Editor-in- Chief-Emeritus of the journal Combinatorial Chemistry & High Throughput Screening. Rathnam passionately advocates the need for innovation and entrepreneurship and the virtues of collaborative partnerships in addressing the pharmaceutical inno- vation crisis, and aggressively warns the threat of scientific misconduct in biomedical sciences. He received his PhD with an award-winning thesis from Sri Venkateswara University, Tirupati, India.

Drug Discovery World Summer 2018

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80